GoldenGolden
Advanced Search
Cybrexa Therapeutics

Cybrexa Therapeutics

Cybrexa Therapeutics is a small Molecule DNA repair Inhibitors.

Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.

Timeline

May 20, 2021
Cybrexa Therapeutics appoints pharmaceutical and financial services veteran Stephen Basso as Chief Financial Officer.
March 11, 2021
Cybrexa Therapeutics raises a $25,000,000 series B round.
June 16, 2017
Cybrexa Therapeutics raises a $6,000,000 series B round from HighCape Partners.
June 2017
Cybrexa Therapeutics raises a $6,000,000 series B round from Connecticut Innovations and HighCape Partners.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
May 20, 2021
BioSpace
Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalexTM Peptide Drug Conjugate (PDC) tumor targeting platform, today announced that it has appointed pharmaceutical and financial services veteran Stephen Basso as Chief Financial Officer.
BioSpace
May 10, 2021
BioSpace
Study to determine safety and tolerability of CBX-12 and establish recommended Phase 2 dose

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.